Proactive Investors - Run By Investors For Investors

Breakfast News - Strongbow Exploration, FairFX Group, Altona Energy and more...

Breakfast News - Strongbow Exploration,  FairFX Group, Altona Energy  and more...

Small Cap Breakfast                

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

936*

Total number of AIM Companies trading:

880*

*as at close of business  4 June 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

137*

Total number of Standard List Companies trading:

124*

*as at close of business  4 June 2018

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

85*

Total number of NEX Growth Market Companies trading:

83*               

*as at close of business  4 June 2018

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

                              

Dish of the day

No Joiners Today

Off the menu  

Gloo Networks has left AIM

                                                

What’s cooking in the IPO kitchen?

NEX Exchange

Stratmin Global Resources RTO of Signature Gold  a specialist Australian gold exploration company focused on the exploration and development of large-scale Intrusion Related Gold System. Offer TBA. Due 6 June.  Will leave AIM under rule 41.

AIM

i-nexus—develops and provides strategy execution software to assist global enterprises in effective execution of their strategic plans and initiatives looking to jon AIM. Offer TBC, expected 19 June

Yellow Cake will use its expertise to generate value through the ownership of physical U3O8 (Uranium) together with a range of activities and opportunities connected with owning physical U3O8. Acquiring supply contract for up to $170m. Offer TBA.

Tekmar— technology provider of protection systems for subsea cable, umbilical and flexible pipes and offshore engineering services—Offshore wind farms and Oil & Gas. Revenue of £21.9m and Adjusted EBITDA of £4.9m Offer TBA

Knights Group— UK regional legal and professional services businesses. FYApr18 rev  £34.9 million and adjusted operating profit was £6.8 million excluding Turner Parkinson (acquiring on IPO).  Offer TBA

Aquis Exchange—a founder-led, pan-European Multilateral Trading Facility and exchange and regulatory technology developer and service provider is looking to join AIM. Offer TBC, expected 20 June.

TransGlobe Energy Corporation—an independent international upstream oil and gas company with headquarters in Calgary, Canada is looking to join AIM. No Capital to be raised, market cap of £131m. Expected 29 June

Block Energy— UK based oil exploration and production company whose main country of operation is the Republic of Georgia.  Raising £5m at 4p. Mkt cap £10.3m. Due 11 June.

Strongbow Exploration (TSX:SBW) intends to dual list on AIM.  Holds rights to the South Crofty underground tin mine, a former producing tin mine located in the towns of Pool and Camborne, Cornwall . The project is estimated to require the Company to raise £25 million over the next 18 months to progress to a production decision. Offer TBS. Due June.

Yew Grove REIT—newly formed Company will pursue its investment objective by investing in a diversified portfolio of Irish commercial property. Offer TBA. Due 10 June

 

Main Market (Premium)

Utilico Global Income—  new actively managed income investment trust raising up to £100 million. Due 22 June.

       

Breakfast Buffet

Premaitha Health (LON:NIPT) 8.61p £33.3m

The molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces a 3-year agreement with one of the most advanced clinical laboratory groups in India, to provide a bespoke, high quality and scalable NIPT solution in the Indian market.

NIPT is relatively new in the Indian market but, with over 26 million births per annum, and increasing awareness of the benefits of NIPT, Premaitha expects that India will be a key growth market for the Company and that this partnership will be a catalyst for the market.

FYMar19E rev £8.8m and £3.7m pre-tax loss,

 

FairFX Group (LON:FFX) 97.26p £151.1m

AGM Statement.

"The Group made two transformational acquis­itions during the year, which have enabled FairFX to significantly broaden its growth opportunities as it makes further advances into the digital banking sector. 

The Group's performance in 2018 to date has been encouraging with continued strong growth. In addition, the Group is already reaping the benefits of the acquisition of City Forex in February 2018 including the migration of the FairFX international payments business onto the City Forex proprietary platform, thus improving efficiencies. The Board expects the Group's trading performance for the full year to be in line with market expectations." PE c.19x.

 

Imaginatik (LON:IMTK) 1.1p £2.47m

Result of strategic review and new funding and Board changes 

Termination of sale process; retention of existing business;

Board and management changes including departure of both Chairman and Chief Executive;

Resultant immediate £750,000 plus reduction in annual costs;

£225,000 of new funds raised;

“The directors note that the Company retains a roster of 38 customers, currently worth annualised revenues of approximately £2.8m. In the last financial year, the Company secured 13 new customers, seven of which are on annual or multi-year contracts consisting of both technology and consulting, adding to the Company's base of recurring revenue.”

 

Cambria Africa (LON:CMB) 1.25p £4.4m

“Cambria is pleased to announce that, further to its announcement of 15 May 2018 it is today posting a circular (the "Circular") to Qualifying Shareholders regarding an Open Offer of up to £4.28m which will include up to £1.60m through the conversion of loans into equity by Ventures Africa Limited”.

Cambria Africa plc is a long term, active investment company, building a portfolio of investments primarily in Zimbabwe. The Company does not have a particular sectoral focus. Its key objective is building a portfolio of companies that are well-positioned to benefit from Zimbabwe’s economic growth and from formalization and modernization of Zimbabwe’s economy.

 

Filta Group Holdings (LON:FLTA) 209p £56.7m

AGM Statement from the  provider of fryer management and other services to commercial kitchens. "The Company has made strong progress in the year to date, with 6 new franchises, including one in both of our newest operating locations Canada and Germany, and a total of 17 MFU sales. Our existing franchises and Company-owned operations are performing in line with management expectations, and we are seeing an increasing contribution from FiltaGMG as our organisational improvements take effect. Despite the adverse impact of a weak US dollar on our revenues through the early part of the year, EBITDA for the year to date is approximately 11% ahead of the same period last year, equating to growth of approximately 23% at a constant exchange rate.” FY Dec 18E rev £13.2m PBT £2.6m

 

Altona Energy (LON:ANR) 0.42p £6.55m

Non-binding MOU with GCAT Energy Group Inc..  GCAT owns the licence to use a patented pyrolysis technology which it intends to use to develop a waste recycling project in Spain. The pyrolysis technology which converts carbon matter into a variety of outputs including syngas, which can be used to generate electricity, carbon black, naptha and diesel. The technology has already been demonstrated successfully and is expected to be suitable for the conversion of thermal coal into these outputs. ,GCAT and the Company have confirmed their intention to negotiate terms under which Altona may be able to invest in the equity of the JV formed to exploit the technology.  In addition, Altona will be granted a licence to use this technology in other specific projects including at the Company's Australian coal project.

 

Gama Aviation (LON:GAMA) 205p £130.4m

AGM Update from the global business aviation services provider.

“Trading across both Air and Ground divisions has been broadly satisfactory although flat compared with last year, with conditions in Europe being somewhat challenging whilst conditions in the US are supporting strong growth.”

“Following the equity placing in March, the Group is confident in delivering its strategic growth plan for 2018. The anticipated investments in US & Middle East Ground are underway and the Group continues to actively review potential acquisition candidates, particularly, in Europe and the Middle East.”

 

Ace Liberty & Stone (NEX:ALSP) 113p £45.3m

“The Company has completed the purchase of an office property at Princes Court, York Road, Leicester at a price of £4.3m. The entire property is let to the Secretary of State for the Environment and occupied by the Leicester Crown Prosecution Service at an annual rent of £0.29m.

This acquisition is the first to be financed by Coutts & Co for the company. The advance of £2.79m is part of a facility agreed for the purchase of three properties.

Dr Tony Ghorayeb, Chairman, commented "The Company is committed to providing good returns to shareholders through dividend payments and increases in the share price. Acquisitions of this type underpin that plan".

 

ECSC (LON:ECSC) 105p £9.6m

The “cyber security services provider, is pleased to be formally launching the new KEPLER Cyber Security Artificial Intelligence (AI) product at today's Infosecurity Europe show in Olympia London. “ 

"KEPLER AI aids our highly skilled and experienced engineers, in both the UK and Australia, process billions of client security events each month.  The technology is in use for all ECSC Managed Service clients receiving 24/7/365 monitoring and alerting services."

We could see no forecasts.

 

Novacyt (LON:NCYT.L) 59.5p £22.4m

The “International specialist in clinical diagnostics, announces that its protein diagnostics division, Lab21 Products (Lab21), has launched a new product for the diagnosis of infectious mononucleosis (IM), also known as glandular fever.

 

PathFlow™ Mononucleosis is a qualitative lateral flow immunoassay for the detection of IM antibodies in the blood. IM is frequently misdiagnosed as a bacterial infection, streptococcal pharyngitis, due to common clinical presentation of the diseases at onset.” This is the first product in a series of high quality, lateral flow immunoassays, which will form part of Novacyt's growing catalogue of rapid infectious disease diagnostics and aid Lab21's position as a leader in microbial diagnostic kits.  

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use